Ipca Laboratories Limited

BSE: 524494 NSE: IPCALAB
Ipca Laboratories Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24239MH1949PLC007837 Incorporated 19 October 1949 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: IPCALAB · BSE: 524494 Public Limited Company pharma Fortune India 500 · #286 Nifty 500
Data last updated
Market Cap
₹48,869 Cr
IPCALAB · NSE
Share Price
₹1,927.80
+0.08% today
Revenue
₹9,646 Cr
FY 2025-26 · +7.9% YoY
EBITDA
₹1,878 Cr
Margin 19.5%
Net Profit
₹1,180 Cr
FY 2025-26 · +38.2% YoY
P/E (TTM)
35.7x
P/B 6.1x
ROE
15.9%
ROCE 19.0%
Debt / Equity
0.14
Interest cover 5.4x

About Ipca Laboratories Limited

Data last updated:

Ipca Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 October 1949 and has been in existence for over 77 years.

Ipca Laboratories is ranked #286 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director Premchand Godha and family are #196 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24239MH1949PLC007837. Its GSTIN is 27AAACI1220M1ZT (Maharashtra). The company holds 30 GST registrations, of which 25 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524494 and NSE: IPCALAB.

The company has an authorised share capital of ₹57.6 Cr and a paid-up capital of ₹25.37 Cr. It was formerly known as The Indian Pharmaceutical Combine Association Ltd. It is led by directors including Ajit Kumar Jain (Managing Director) and Pranay Premchand Godha (Managing Director).

Its last annual general meeting (AGM) was held on 11 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹9,646.33 Cr, a growth of 7.9% compared to the previous year. For the same year it recorded a net profit of ₹1,180.12 Cr (net margin 12.2%) and EBITDA of ₹1,877.63 Cr (EBITDA margin 19.5%). The net worth stands at ₹8,063.81 Cr (up 16.1% YoY). Total assets are valued at ₹10,431 Cr (up 5.9% YoY).

The company has about 17,422 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries and 2 joint ventures.

The company is associated with 2 brands: Ipca Laboratories and Ipca Laboratories. As per MCA filings, the company has open charges of ₹2,303.63 Cr and satisfied charges of ₹2,406.67 Cr on record. Court records list 332 cases involving the company, including 192 filed by the company and 140 filed against it; 74 cases are pending. The company has 52 deals on record (47 market trades, 3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹365.34 Cr; the latest was in December 2024. Its 9 peer companies in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Torrent Pharmaceuticals Ltd with revenue of ₹11,539 Cr. The company has 16 MSME Form 1 returns on record between 2019 and 2024, listing 1,706 overdue payments to 417 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ipca.com.

Company details

CIN L24239MH1949PLC007837
Registration Number 007837
Incorporation Date 19 October 1949
ROC Mumbai
Listing Status Listed - Listed on NSE (IPCALAB); Listed on BSE (524494)
Company Status Active
Date of Last AGM 11 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Ajit Kumar Jain Managing Director Pranay Premchand Godha Managing Director Premchand Gigalal Godha Whole-Time Director

Recognitions & Rankings of Ipca Laboratories

Fortune India 500 2025 edition
Rank#286
Total income
₹9,078 Cr
Profit
₹738 Cr
Last year #292
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#163
Valuation
₹38,670 Cr
2023 #173 2022 #178 2021 #150
Stock market indices
Nifty 500 BSE 500

Contact details

Ipca Laboratories Limited's registered office is in Mumbai, Maharashtra. Its website is ipca.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    ipca.com
  • Social Media
  • Registered Address
    48 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, India – 400067
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers

To see the full contact details of Ipca Laboratories Limited, buy the company report.

Comprehensive company report
Ipca Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Ipca Laboratories operates two associated brands: Ipca Laboratories and Ipca Laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Ipca Laboratories
APIs and drug formulations are manufactured for therapeutic segments.ipca.com
Ipca Laboratories
Ipca Laboratories is engaged in pharmaceutical manufacturing and distribution.ipcalabs.com

Business activity

The main business activity of Ipca Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Ipca Laboratories Limited, buy the company report.

Financials of Ipca Laboratories Limited

FY 2025-26 filings available

Ipca Laboratories Limited reported revenue of ₹9,646.33 Cr (up 7.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹9,646 Cr
+7.9% YoY
EBITDA
₹1,878 Cr
+23.2% YoY
Profit After Tax
₹1,180 Cr
+38.2% YoY
Net Worth
₹8,064 Cr
+16.1% YoY
Total Assets
₹10,431 Cr
+5.9% YoY
Total Debt
₹809 Cr
-40.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue9,6468,9407,7056,2445,8305,4204,619
Revenue growth+7.9%+16.0%+23.4%+7.1%+7.6%+17.3%-
EBITDA1,8781,5241,1489291,3131,548902
EBITDA margin+19.5%+17.1%+14.9%+14.9%+22.5%+28.6%+19.5%
Profit before tax1,5731,1318437451,1361,389739
Net profit1,1808545944548851,134597
Net profit margin+12.2%+9.6%+7.7%+7.3%+15.2%+20.9%+12.9%
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
Balance sheet
Total assets10,4319,8489,2537,4446,4215,0224,176
Net worth8,0646,9486,3325,8425,4924,7023,627
Total debt8091,3631,4381,481807265501
Cash & bank5653442971,853641365181
Net working capital4,0463,5863,4403,8732,6622,1311,676
Cash flow
Cash from operations1,1421,3219458068561,090570
Cash from investing(247)(870)(1,215)(725)(851)(521)(509)
Cash from financing(754)(283)(553)507427(306)(137)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,7882,3882,3922,5562,3092,2472,2452,355
Revenue growth (YoY)+20.8%+6.3%+6.6%+8.6%+10.3%---
Other income25.2693.7437.8427.8632.6625.8220.1126.26
EBITDA670438533487416224463441
EBITDA margin+24.0%+18.3%+22.3%+19.0%+18.0%+10.0%+20.6%+18.7%
Depreciation11110710810310010098.46100
Interest11.8820.2017.6219.6118.5121.5116.8122.56
Profit before tax572404446392331128368345
Tax14995.0581.9310896.0962.2290.5999.39
Net profit42330936428423465.78277245
EPS (₹)15.8411.7912.8611.149.192.679.789.05
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue7,3376,6786,1665,8155,4385,1394,338
Revenue growth+9.9%+8.3%+6.1%+6.9%+5.8%+18.5%-
EBITDA1,7521,2461,0809141,2411,517918
EBITDA margin+23.9%+18.7%+17.5%+15.7%+22.8%+29.5%+21.2%
Profit before tax1,5321,0008227501,0741,380785
Net profit1,1368206004888531,132642
Net profit margin+15.5%+12.3%+9.7%+8.4%+15.7%+22.0%+14.8%
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
Balance sheet
Total assets8,3437,8567,5517,3656,2965,0284,185
Net worth7,9796,8926,3495,8775,4764,7533,678
Total debt2959061,1521,440776236474
Cash & bank3631651131,706596307152
Net working capital2,4032,1042,1743,6492,5222,0371,615
Cash flow
Cash from operations1,3781,3748317628321,096561
Cash from investing(697)(739)(1,355)(710)(812)(560)(499)
Cash from financing(745)(428)(465)506426(307)(139)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,1191,8141,8451,9301,7471,6381,6631,811
Revenue growth (YoY)+21.3%+10.7%+11.0%+6.6%+11.6%---
Other income17.4229.8817.8221.9225.0221.4917.4117.00
Total expenses1,5421,4141,3681,4661,3401,5611,2521,409
EBITDA57840147746540777.05411402
EBITDA margin+27.3%+22.1%+25.9%+24.1%+23.3%+4.7%+24.7%+22.2%
Depreciation74.6170.3168.5766.8663.1365.1962.8162.65
Interest5.0410.489.5111.4612.0616.2010.1717.25
Profit before tax51535041740835717.15356339
Tax14287.5611410494.7182.2087.9695.09

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 30 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,7882,3882,3922,5562,3092,2472,2452,355
Revenue growth (YoY)+20.8%+6.3%+6.6%+8.6%+10.3%---
Other income25.2693.7437.8427.8632.6625.8220.1126.26
EBITDA670438533487416224463441
EBITDA margin+24.0%+18.3%+22.3%+19.0%+18.0%+10.0%+20.6%+18.7%
Depreciation11110710810310010098.46100
Interest11.8820.2017.6219.6118.5121.5116.8122.56
Profit before tax572404446392331128368345
Tax14995.0581.9310896.0962.2290.5999.39
Net profit42330936428423465.78277245
EPS (₹)15.8411.7912.8611.149.192.679.789.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue9,6468,9407,7056,2445,8305,4204,619
Revenue growth+7.9%+16.0%+23.4%+7.1%+7.6%+17.3%-
Other income19292.8019312666.5762.8467.00
Total expenses7,7697,4166,5575,3154,5173,8723,717
Employee cost2,1601,9841,7081,2881,1771,014921
EBITDA1,8781,5241,1489291,3131,548902
EBITDA margin+19.5%+17.1%+14.9%+14.9%+22.5%+28.6%+19.5%
Depreciation418398357262232209210
Interest79.0987.8414148.1911.2012.2719.77
Profit before tax1,5731,1318437451,1361,389739
Tax381344313253225240135
Net profit1,1808545944548851,134597
Net profit margin+12.2%+9.6%+7.7%+7.3%+15.2%+20.9%+12.9%
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.3725.3725.3725.3725.3725.3725.27
Reserves & surplus8,0386,9236,3075,8175,4674,6763,590
Shareholders' funds (net worth)8,0646,9486,3325,8425,4924,7023,627
Minority interest1,4601,4401,39573.3076.9214.5313.63
Secured loans7041,1561,210858555141324
Unsecured loans105206229623253124176
Total debt8091,3631,4381,481807265501
Total liabilities10,4319,8489,2537,4446,4215,0224,176
Assets
Gross block7,6926,9957,0214,3653,7593,2122,986
Net block4,6274,2674,5542,7512,4182,0722,059
Capital work in progress773622343140306235133
Investments844980862626989505310
Inventories2,7312,5602,4711,7431,8581,5951,323
Sundry debtors2,0141,8841,687989911812895
Cash & bank balances5653442971,853641365181
Loans & advances430415522280318272218
Total current assets5,7405,2044,9774,8663,7273,0432,617
Total current liabilities1,6941,6181,5389931,065913942
Net working capital4,0463,5863,4403,8732,6622,1311,676
Total assets10,4319,8489,2537,4446,4215,0224,176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash9257561,579991559295371
Net cash from operating activities1,1421,3219458068561,090570
Net cash from investing activities(247)(870)(1,215)(725)(851)(521)(509)
Net cash from financing activities(754)(283)(553)507427(306)(137)
Net change in cash142169(823)588432264(75.53)
Closing cash5653442971,853641365181
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+7.9%+16.0%+23.4%+7.1%+7.6%+17.3%-
EBITDA growth+23.2%+32.8%+23.5%-29.2%-15.2%+71.5%-
PBT growth+39.0%+34.2%+13.1%-34.4%-18.2%+88.0%+35.2%
Net income growth+38.2%+43.8%+30.7%-48.7%-21.9%+90.0%-
Revenue CAGR (3Y)+15.6%+15.3%+12.4%+10.6%+15.9%+18.5%+13.5%
EBITDA CAGR (3Y)+26.4%+5.1%-9.5%+1.0%+23.7%+50.5%+26.2%
Profitability & leverage
Net income margin+12.4%+8.8%+6.9%+7.9%+15.6%+21.2%+13.1%
Return on capital employed+19.0%+17.1%+12.9%+11.6%+20.2%+30.6%+19.5%
Return on net worth+15.9%+13.6%+8.7%+8.7%+17.9%+27.6%+17.9%
Debt / equity0.140.210.240.200.110.090.14
Long-term debt / equity0.050.090.110.100.040.020.04
Interest cover5.427.8017.807.221.040.922.86
Efficiency & per share
Fixed asset turnover1.311.281.351.541.671.751.65
Inventory turnover3.653.553.663.473.383.713.88
Debtors turnover4.955.015.766.576.776.355.90
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
Dividend per share (₹)0.004.004.004.008.008.005.00
Book value per share (₹)317.85273.88249.59230.27216.47370.65286.15
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,1191,8141,8451,9301,7471,6381,6631,811
Revenue growth (YoY)+21.3%+10.7%+11.0%+6.6%+11.6%---
Other income17.4229.8817.8221.9225.0221.4917.4117.00
Total expenses1,5421,4141,3681,4661,3401,5611,2521,409
EBITDA57840147746540777.05411402
EBITDA margin+27.3%+22.1%+25.9%+24.1%+23.3%+4.7%+24.7%+22.2%
Depreciation74.6170.3168.5766.8663.1365.1962.8162.65
Interest5.0410.489.5111.4612.0616.2010.1717.25
Profit before tax51535041740835717.15356339
Tax14287.5611410494.7182.2087.9695.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue7,3376,6786,1665,8155,4385,1394,338
Revenue growth+9.9%+8.3%+6.1%+6.9%+5.8%+18.5%-
Other income94.6471.2911111152.9262.2464.69
Total expenses5,5855,4325,0874,9004,1973,6233,420
Employee cost1,6561,4791,3361,1931,102949871
EBITDA1,7521,2461,0809141,2411,517918
EBITDA margin+23.9%+18.7%+17.5%+15.7%+22.8%+29.5%+21.2%
Depreciation269252246229210188179
Interest45.4665.0612346.3410.4111.1318.84
Profit before tax1,5321,0008227501,0741,380785
Tax400349292245214239133
Net profit1,1368206004888531,132642
Net profit margin+15.5%+12.3%+9.7%+8.4%+15.7%+22.0%+14.8%
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.3725.3725.3725.3725.3725.3725.27
Reserves & surplus7,9546,8666,3235,8525,4504,7273,640
Shareholders' funds (net worth)7,9796,8926,3495,8775,4764,7533,678
Secured loans235726991858555114298
Unsecured loans60.06180161582222123176
Total debt2959061,1521,440776236474
Total liabilities8,3437,8567,5517,3656,2965,0284,185
Assets
Gross block5,0374,3884,1663,8893,3652,8992,689
Net block2,9692,5372,5242,4792,1531,8691,841
Capital work in progress45949017512329718284.19
Investments2,5362,6932,6541,0571,339868649
Inventories1,7081,5421,6771,6601,7801,5171,267
Sundry debtors1,2721,1661,027926824774839
Cash & bank balances3631651131,706596307152
Loans & advances304255282260306285215
Total current assets3,6473,1283,0994,5523,5052,8842,474
Total current liabilities1,2441,024925903983847859
Net working capital2,4032,1042,1743,6492,5222,0371,615
Total assets8,3437,8567,5517,3656,2965,0284,185
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash7225151,505946500272348
Net cash from operating activities1,3781,3748317628321,096561
Net cash from investing activities(697)(739)(1,355)(710)(812)(560)(499)
Net cash from financing activities(745)(428)(465)506426(307)(139)
Net change in cash(64.08)207(990)559446229(76.37)
Closing cash3631651131,706596307152
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.9%+8.3%+6.1%+6.9%+5.8%+18.5%-
EBITDA growth+40.7%+15.3%+18.1%-26.3%-18.2%+65.2%-
PBT growth+53.3%+21.6%+9.6%-30.1%-22.2%+75.8%+40.8%
Net income growth+38.5%+36.7%+22.9%-42.7%-24.7%+76.5%-
Revenue CAGR (3Y)+8.1%+7.1%+6.3%+10.3%+14.7%+17.2%+11.8%
EBITDA CAGR (3Y)+24.2%+0.1%-10.7%-0.1%+21.3%+50.5%+28.3%
Profitability & leverage
Net income margin+15.4%+9.7%+8.6%+8.7%+15.8%+22.2%+15.0%
Return on capital employed+19.5%+17.2%+14.1%+11.7%+19.2%+30.2%+20.6%
Return on net worth+15.2%+12.4%+9.8%+8.9%+16.8%+27.1%+19.2%
Debt / equity0.080.160.210.200.100.080.13
Long-term debt / equity0.040.080.100.090.040.010.03
Interest cover3.076.5514.716.761.010.842.55
Efficiency & per share
Fixed asset turnover1.561.561.531.601.741.841.71
Inventory turnover4.524.153.703.383.303.693.76
Debtors turnover6.026.096.316.646.806.375.94
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
Dividend per share (₹)6.004.004.004.004.008.005.00
Book value per share (₹)314.52271.64250.24231.66215.84374.67290.11

To see the full year-wise statements and ratios of Ipca Laboratories Limited, buy the company report.

Board of directors of Ipca Laboratories Limited

Ipca Laboratories has 8 current directors and 11 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Narendra Mairpady
Also directs: Kesar Enterprises Limited, Saatvik Green Energy Limited, Equippp Social Impact Technologies Limited and 5 more
Director20 Oct 20224 Years 0 MonthsCurrent
Ajit Kumar Jain
Also directs: Ipca Foundation
Managing Director21 Aug 200917 Years 2 MonthsCurrent
Kamal Kishore Seth
Also directs: Ipca Foundation, Gufic Biosciences Limited, Indo-Vietnamese Chamber of Commerce and Industry
Director29 Mar 20197 Years 7 MonthsCurrent
Pranay Premchand Godha
Also directs: Xgrow Traders LLP, Kaygee Laboratories Private Limited, Kaygee Investments Private Limited and 2 more
Managing Director30 Jul 200917 Years 3 MonthsCurrent
Premchand Gigalal Godha
Also directs: Ipca Foundation, Xgrow Traders LLP, Kaygee Laboratories Private Limited and 1 more
Whole-Time Director31 Jan 201214 Years 8 MonthsCurrent
Prashant Godha
Also directs: Ipca Foundation, Xgrow Traders LLP, Kaygee Laboratories Private Limited and 5 more
Director28 Jul 201115 Years 3 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Ipca Laboratories Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Torrent Pharmaceuticals Ltd₹11,539 Cr (FY 2025)7.0%Ahmedabad, Gujarat, India
Serum Institute of India Private Limited₹10,854 Cr (FY 2025)-2.0%Pune, Maharashtra, India
Biocon Biologics Limited₹10,144 Cr (FY 2025)13.0%Bengaluru, Karnataka, India
Divi's Laboratories Limited₹9,712 Cr (FY 2025)19.0%Hyderabad, Telangana, India
Macleods Pharmaceuticals Ltd₹9,671.68 Cr (FY 2025)5.0%Mumbai, Maharashtra, India
Ipca Laboratories Limitedthis company₹9,646.33 Cr (FY 2026)₹1,180.12 Cr12.2%7.9%17,422Mumbai, Maharashtra, India
Abbott Healthcare Private Limited₹8,811.32 Cr (FY 2025)3.0%Mumbai, Maharashtra, India
Deccan Fine Chemicals (India) Private Limited₹8,738.51 Cr (FY 2024)-1.0%Hyderabad, Telangana, India
Emcure Pharmaceuticals Limited₹7,963.26 Cr (FY 2025)19.0%Pune, Maharashtra, India
Mylan Laboratories Limited₹7,503.56 Cr (FY 2025)-23.0%Hyderabad, Telangana, India

To see the full peer comparison of Ipca Laboratories Limited, buy the company report.

Auditor

Ipca Laboratories Limited is audited by Natvarlal Vepari & Co for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Natvarlal Vepari & CoFY 2024106971W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 44.70%, foreign institutional investors hold 10.70%, domestic institutional investors hold 37.40% and retail and other public shareholders hold 7.20%.

Promoters: 44.70%DII (Domestic Institutional): 37.40%FII (Foreign Institutional): 10.70%Retail & Others: 7.20%
Sep 2026
QUARTER
44.70% Promoters
37.40% DII (Domestic Institutional)
10.70% FII (Foreign Institutional)
7.20% Retail & Others
Promoter holding - history
Now 44.70% · Sep 2026High 44.70% · Dec 2025Low 44.70% · Dec 2025
43%43.8%44.5%45.3%46%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 44.70%Mar 2026: 44.70%Jun 2026: 44.70%Sep 2026: 44.70%44.70%44.70%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters44.70%44.70%44.70%44.70%
Public55.30%55.30%55.30%55.30%

Charges & borrowings

Open charges
₹2,303.63 Cr
Satisfied charges
₹2,406.67 Cr
Breakdown by lending institutions
Idbi Trusteeship Services Limited₹1,510.00 Cr
Hdfc Bank Limited₹691.22 Cr
Kotak Mahindra Bank Limited₹29.70 Cr
Canara Bank₹28.22 Cr
Icici Banking Corporation Ltd.₹20.00 Cr
Others₹24.49 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
29 Aug 2023100775715Hdfc Bank Limited₹300 CrOpen
07 Oct 2022100619945Hdfc Bank Limited₹391.22 CrOpen
25 Mar 2022100555603Others₹1.9 CrOpen
11 Mar 2022100555580Others₹10 LakhOpen
03 May 201310425025Idbi Trusteeship Services Limited₹790 CrOpen

To see the full charge records of Ipca Laboratories Limited, buy the company report.

Total charge records: 108 View all charges

Deals & funding

Ipca Laboratories Limited has 52 deals on record (47 market trades, 3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹365.34 Cr; the latest was in December 2024.

Total deals
52
Market trades
47
Secondary share transfers
3
Funding rounds
2
Disclosed funding
₹365.34 Cr

Deals on record (5 of 52)

WhenDealAmountParties
Sep 2020Market trade₹41.74 CrBuyer: Kaygee Investments Private Limited
Seller: Makers Laboratories Ltd
Dec 2013Market trade₹22.95 CrBuyer: Kaygee Laboratories Private Limited
Seller: an individual
Oct 2007Market trade₹211.92 CrBuyer: Kaygee Investments Private Limited , Kaygee Laboratories Private Limited , an individual
Seller: Chandurkar Investments Pvt Ltd
Jul 2007Market trade₹110.19 CrBuyer: Aig Global Investment Group Mutual Fund A/C Aigindia Eqfund, Mirae Asset India Solomon Equity Investment Trust, Sundaram Mutual Fund A/C Sundaram Select Midcap
Seller: Chandurkar Investments Pvt Ltd
Mar 2006Market trade₹7.1 CrBuyer: Chamanlal Desai Huf
Seller: CD Equifinance Private Limited

To see the full deal history of Ipca Laboratories Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Ipca Laboratories Limited was last rated by Care on 06 Sep 2021.

Rating agencyRated onRating
Care06 Sep 2021

To see the full credit ratings and regulatory alerts of Ipca Laboratories Limited, buy the company report.

MSME payment delays

Ipca Laboratories Limited has 16 MSME Form 1 returns on record between 2019 and 2024, listing 1,706 overdue payments to 417 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 417)

SupplierAmount dueDue sinceReported on
an individual supplier
Sanwariya Packaging Private Limited
Cosmoplast Polycontainer LLP
Raj Barcode Systems Private Limited
an individual supplier

To see the full MSME payment records of Ipca Laboratories Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Ipca Laboratories has 3 subsidiary companies, 2 joint ventures, and 3 associated companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

3
Subsidiary companies
2
Joint ventures
3
Associated companies
Key subsidiaries
Company NameCINShares held
Unichem Laboratories LimitedL99999MH1962PLC012451
Trophic Wellness Private LimitedU24100MH2010PTC206526
Ipca FoundationU85300MH2021NPL360586

To see the full group structure of Ipca Laboratories Limited, buy the company report.

Employees & EPFO

Ipca Laboratories Limited has a workforce of 17,422 employees on its EPFO records as of Feb 28, 2025, across 17 active EPFO establishments.

Employee count
17,422
Active EPFO establishments
17
Employee growth
-6.99%

GST

Ipca Laboratories has 30 GST registrations: 25 active and 5 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
30
Active
25
Cancelled / inactive
5
GSTINStateStatusRegistered on
27AAACI1220M1ZTMaharashtraActive01 Jul 2017
27AAACI1220M2ZSMaharashtraActive07 Jul 2017
05AAACI1220M1ZZUttarakhandActive01 Jul 2017
06AAACI1220M1ZXHaryanaActive01 Jul 2017

To see the full GST registrations and return filing status of Ipca Laboratories Limited, buy the company report.

Recent activity

Ipca Laboratories Limited has 29 board changes on record since 1975: 19 appointments and 10 cessations. The latest: Premnath Manisha ceased to be Director on 21 Sep 2024.

Filing
Ipca Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge registered on 24 Jan 2025 via Charge ID 101041701 with Citi Bank N.A. was fully satisfied on 11 Feb 2026.
Charges
A charge registered on 08 Aug 2023 via Charge ID 100768745 with The Hongkong And Shanghai Banking Corporation Limited was fully satisfied on 09 Jan 2026.
Charges
A charge registered on 02 Aug 2022 via Charge ID 100633351 with Jp Morgan Chase Bank, N.A. was fully satisfied on 07 Jan 2026.
AGM
Ipca Laboratories Limited last Annual general meeting of members was held on 11 Aug 2025 as per latest MCA records.
Charges
A charge with Citi Bank N.A. amounted to Rs. 166.60 Cr with Charge ID 101041701 was registered on 24 Jan 2025.
Ceased
Premnath Manisha ceased to be Director.
Appointed
Vivek Keshav Shiralkar was appointed as Director.
Ceased
Anand Trimbak Kusre ceased to be Director.
Appointed
Swati Arvind Patankar was appointed as Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 300.00 Cr with Charge ID 100775715 was registered on 29 Aug 2023.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 123.71 Cr with Charge ID 100768745 was registered on 08 Aug 2023.

236 earlier events are in the company report.

News

Frequently asked questions

Ipca Laboratories is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 October 1949 (77+ years old) and is registered under CIN L24239MH1949PLC007837. Listed on BSE: 524494 and NSE: IPCALAB.

Ipca Laboratories reported revenue of ₹9,646.33 Cr for FY 2025-26 (up 7.9% YoY) based on consolidated financials.

Ipca Laboratories has 8 current directors:

The latest financial statements of Ipca Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 11 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Ipca Laboratories is 27AAACI1220M1ZT, registered in Maharashtra. The company has 30 GST registrations in all, of which 25 are active and 5 are cancelled or inactive. Other active GSTINs include 27AAACI1220M2ZS (Maharashtra), 05AAACI1220M1ZZ (Uttarakhand), 06AAACI1220M1ZX (Haryana).

The CIN (Corporate Identification Number) of Ipca Laboratories is L24239MH1949PLC007837. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Ipca Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 524494) and NSE (symbol: IPCALAB).

Ipca Laboratories has 332 court cases on record: 192 filed by the company and 140 filed against it. 74 are pending. Most are in the high courts.

Ipca Laboratories was incorporated on 19 October 1949, making it 77+ years old. It is registered with the Registrar of Companies, Mumbai.

Ipca Laboratories has 52 deals on record (47 market trades, 3 secondary share transfers, 2 funding rounds), with disclosed funding of ₹365.34 Cr; the latest was in December 2024.

The peers of Ipca Laboratories by revenue are Torrent Pharmaceuticals Ltd, Serum Institute of India Private Limited, Biocon Biologics Limited, Divi's Laboratories Limited, Macleods Pharmaceuticals Ltd and 4 more, all in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Premnath Manisha ceased to be Director on 21 Sep 2024. Vivek Keshav Shiralkar was appointed as Director on 29 May 2024. Anand Trimbak Kusre ceased to be Director on 01 Apr 2024. Ipca Laboratories has 29 board changes on record in total.